Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma.
暂无分享,去创建一个
Laurence J Miller | L. Miller | G. Hayes | P. Carrigan | Gregory M Hayes | Patricia E Carrigan | Alison M Beck
[1] J. Manley,et al. SR proteins and splicing control. , 1996, Genes & development.
[2] H. Burris. Recent updates on the role of chemotherapy in pancreatic cancer. , 2005, Seminars in oncology.
[3] G. Chalepakis,et al. SR protein-specific kinase 1 is highly expressed in testis and phosphorylates protamine 1. , 1999, Nucleic acids research.
[4] Murray Korc,et al. Expression of the IIIc variant of FGF receptor-1 confers mitogenic responsiveness to heparin and FGF-5 in TAKA-1 pancreatic ductal cells , 2001, International journal of gastrointestinal cancer.
[5] T. Pawson,et al. SRPK1 and Clk/Sty Protein Kinases Show Distinct Substrate Specificities for Serine/Arginine-rich Splicing Factors* , 1996, The Journal of Biological Chemistry.
[6] J. Diehl,et al. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. , 2003, Cancer research.
[7] J. Tazi,et al. The spliceosome: a novel multi-faceted target for therapy. , 2005, Trends in biochemical sciences.
[8] L. Miller,et al. Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma. , 2002, Gastroenterology.
[9] R. DePinho,et al. Pancreatic cancer biology and genetics , 2002, Nature Reviews Cancer.
[10] M B Roth,et al. SR proteins: a conserved family of pre-mRNA splicing factors. , 1992, Genes & development.
[11] L. Miller,et al. A misspliced form of the cholecystokinin-B/gastrin receptor in pancreatic carcinoma: role of reduced sellular U2AF35 and a suboptimal 3'-splicing site leading to retention of the fourth intron. , 2002, Cancer research.
[12] G. Snow,et al. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] M. Tsao,et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. , 2000, The American journal of pathology.
[14] F. Pattou,et al. Rapid purification of human ductal cells from human pancreatic fractions with surface antibody CA19-9. , 2004, Biochemical and biophysical research communications.
[15] Martin Hofmann,et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.
[16] James Stévenin,et al. Broad specificity of SR (serine/arginine) proteins in the regulation of alternative splicing of pre-messenger RNA. , 2004, Progress in nucleic acid research and molecular biology.
[17] R H Hruban,et al. Progression model for pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] A. Lowy,et al. Surgery for pancreatic cancer: recent controversies and current practice. , 2005, Gastroenterology.
[19] A. W. Boersma,et al. SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. , 2001, Cancer research.
[20] H. Friess,et al. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents , 2002, Cancer Chemotherapy and Pharmacology.
[21] J. Berlin,et al. Treatment for pancreatic cancer: current therapy and continued progress. , 2005, Gastroenterology.
[22] M. Hagiwara,et al. Novel SR-protein-specific kinase, SRPK2, disassembles nuclear speckles. , 1998, Biochemical and biophysical research communications.
[23] M. Tsao,et al. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. , 1996, The American journal of pathology.
[24] C. Mcginn,et al. Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. , 2002, International journal of radiation oncology, biology, physics.
[25] Yumei Zhang,et al. Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis. , 2004, Experimental cell research.
[26] F. Kittrell,et al. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis , 1999, Oncogene.
[27] M. Hollingsworth,et al. Human MUC4 mucin cDNA and its variants in pancreatic carcinoma. , 2000, Journal of biochemistry.
[28] H. Seno,et al. Identification of a novel alternative splicing of human FGF receptor 4: soluble-form splice variant expressed in human gastrointestinal epithelial cells. , 2000, Biochemical and biophysical research communications.
[29] Dirk G Kieback,et al. Expression of splicing factors in human ovarian cancer. , 2004, Oncology reports.
[30] T. Nilsen. The spliceosome: the most complex macromolecular machine in the cell? , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.
[31] L. Dwyer-Nield,et al. Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: Implications for pre‐mRNA processing , 2004, Molecular carcinogenesis.
[32] K. Arden,et al. Localization of serine kinases, SRPK1 (SFRSK1) and SRPK2 (SFRSK2), specific for the SR family of splicing factors in mouse and human chromosomes. , 1999, Genomics.
[33] E. Wiemer,et al. Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. , 2004, Neoplasia.
[34] L. Cantley,et al. SRPK2: A Differentially Expressed SR Protein-specific Kinase Involved in Mediating the Interaction and Localization of Pre-mRNA Splicing Factors in Mammalian Cells , 1998, The Journal of cell biology.
[35] T. Uchiyama,et al. Serological identification of adult T‐cell leukaemia‐associated antigens , 2005, British journal of haematology.
[36] Xiang-Dong Fu,et al. Phosphorylation-dependent and -independent Nuclear Import of RS Domain-containing Splicing Factors and Regulators* , 2003, The Journal of Biological Chemistry.
[37] H. Kalthoff,et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria‐mediated apoptosis , 2004, International journal of cancer.